Steroid drug purchased for COVID patients in poor countries


GENEVA, July 3 (Reuters) – An initial purchase of the steroid dexamethasone, shown to be effective in treating severe or critical COVID-19 patients, will be made for up to 4.5 million people in low- and middle-income countries, agencies said on Friday.

The U.N. Children’s Fund (UNICEF) is negotiating the advance purchase under the deal led by UNITAID and Wellcome, as part of the World Health Organization’s plan to accelerate access to therapeutics, a joint statement said.

“With this advanced purchase we aim to ensure equitable access for low- and middle-income countries for treatment of COVID-19 with the life-saving drug dexamethasone, and avoid shortages resulting from high-levels of demand from other parts of the world,” said Philippe Duneton, acting executive director of UNITAID. (Reporting by Stephanie Nebehay; Editing by Alison Williams)

Latest articles

A family’s $35 billion fortune evaporates in a blink: the story of Germany’s Schaeffler family

© 2020 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy...

Mika Shares Letter to the Lebanese People ‘Devastated by the Apocalypse’

The British singer, who has Lebanese roots, shared in the country’s grief over the deadly Beirut blast. A massive warehouse explosion in Beirut last...

Hong Kong, Chinese officials jeer at U.S. sanctions over security law

Hong Kong's leader and China's top representative in the city took pot shots at the United States on Saturday after the Trump administration...

In Pandemic and in Geopolitics, China is Winning

As the global health crisis continues to...

Related articles

Leave a reply

Please enter your comment!
Please enter your name here